Eli Lilly completes acquisition of Verve Therapeutics for $10.50/share plus CVR

Verve Therapeutics, Inc.

Tender offer expired July 23, 2025, with 55.7% of shares validly tendered; all conditions satisfied.
Merger completed July 25, 2025; Verve became an indirect wholly-owned subsidiary of Eli Lilly.
Stockholders received $10.50 per share in cash plus one CVR with potential $3.00 milestone payment.
Verve common stock delisted from Nasdaq; registration to be terminated.
Board of directors replaced with Eli Lilly designees; prior directors resigned.

item 1.02item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.